ClinicalTrials.gg

Program

JAK2V617F Inhibitor PRT12396

Its studies are mostly in Polycythemia Vera, led by Prelude Therapeutics.

Furthest: phase 1, since Feb 26, 20261 company-led study, 1 open or runningNext primary completion: Apr 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Prelude Therapeutics11 open or runningphase 1since Feb 26, 2026Feb 26, 2026Apr 2028phase 1 · NCT07469891

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2026First study: phase 1 study in Polycythemia VeraFirst studyNCT07469891 · 100 planned · United States, Australia, France and more

Ahead

  1. Apr 2028Primary completion: phase 1 study in Polycythemia VeraNCT07469891

TargetBeta

JAK2 →read by rule
“An orally bioavailable specific pseudokinase (JH2)-binding inhibitor of the Janus-associated kinase 2 (JAK2) mutation JAK2V617F, ”NCIt, by rule

Other programs on JAK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
baricitinibruleEli Lillyphase 459
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
delgocitinibruleLEO Pharmaphase 321
pacritinibruleSwedish Orphan Biovitrumphase 318
momelotinibruleGlaxoSmithKlinephase 317
flonoltinibruleChengdu Zenitar Biomedical Technologyphase 37
JAK2 Inhibitor TQ05105Sino Biopharmaceuticalphase 216

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07469891Polycythemia Vera · United States, Australia, France and more1RecruitingApr 2028100

How it is read

Names in the registry

  • “PRT12396”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.